Systemic Lupus Erythematous SLE Drugs Market

Systemic Lupus Erythematous SLE Drugs Market


Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis, thrombosis, and myositis. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening severity. It is also called as drug-induced lupus erythematosus due to common observation against drugs such as isoniazid, hydralazine and procainamide. Currently, there is no complete treatment for SLE. While only two biologic agents have been approved by FDA to treat SLE, synthetic drugs are still the mainstay of therapy in SLE. Based on available evidence, azathioprine and mycophenolate mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug in SLE because of the multiple beneficial effects of this agent.

Systemic Lupus Erythematous (SLE) Drugs Market:  Drivers & Restraints                               

Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market. Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market. Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market.

Systemic Lupus Erythematous (SLE) Drugs Market:  Segmentation

The global systemic lupus erythematous drugs market is classified on the basis of molecule and region.

Based on type of molecule, the global systemic lupus erythematous drugs market is segmented into the following:

Corticosteroids

Prednisone

Cortisone

Hydrocortisone

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

Over-the-counter NSAIDs include

Ibuprofen (Motrin)

Naproxen (Naprosyn)

Prescription versions include

Indomethacin (Indocin)

Nabumetone (RELAFEN)

Celecoxib (Celebrex)

Anti-Inflammatories

Aspirin

Acetaminophen (Tylenol)

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Hydroxychloroquine (Plaquenil).

Cyclosporine (Gengraf, Neoral, Sandimmune)

Azathioprine (Azasan, Imuran)

Antimalarials

Chloroquine (Aralen)

Hydroxychloroquine (Plaquenil)

BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)

Belimumab (Benlysta)

Immunosuppressive Agents/Immune Modulators

Azathioprine (Imuran)

Methotrexate (Rheumatrex)

Cyclophosphamide (Cytoxan)

Anticoagulants

Low-dose aspirin

Heparin (Calciparine, Liquaemin)

Warfarin (Coumadin)

Systemic Lupus Erythematous (SLE) Drugs Market:  Overview

Global systemic lupus erythematous drugs market growth is fast in North American region and is estimated to project remarkable CAGR growth throughout forecast period. In North America, the SLE is more prevalent among Hispanics, Asians, and Native Americans according to Centers for Disease Control and Prevention (CDC). The second largest and fastest growing global systemic lupus erythematous drugs market is Europe and is projected to reach nearly US$ 550 Mn and register a double digit CAGR due to higher prevalence of SLE in Europe. Among the European countries Sweden, Iceland, Spain had the highest prevalence according to Lupus Journal article, published in 2006. A drug called hydroxychloroquine being the last drug was approved by FDA in 1955 for SLE treatment. Recently, a drug called belimumab has been approved by FDA after 50 years long gap specifically for SLE on March 9, 2011. It is the first ever targeted biological drug for the treatment of SLE patients developed by Human Genome Sciences Inc. in collaboration with GlaxoSmithKline. It will be the primary driver for global systemic lupus erythematous drugs market growth in the US, France, Germany, Italy Spain, the UK and Japan. Benlysta will lead market sales in coming years because of its excellent safety profile as well as proven efficacy in clinical trials. NSAIDS such as Ibuprofen and aspirin are widely prescribed drugs for suppressing symptoms of SLE. Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral (Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for SLE treatment. Additionally, the entry of four first-in-class (FIC) biologics such as Bristol-Myers Squibb’s Orencia (abatacept), atacicept, epratuzumab and LY2127399 are anticipated to show a major role in the expansion of the global systemic lupus erythematous drugs market. 

Systemic Lupus Erythematous (SLE) Drugs Market:  Key Players

The global systemic lupus erythematous drugs market key players are Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, accessories and applications.

The report covers exhaustive analysis on:

Market Segments

Market Dynamics

Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico, Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, BENELUX)

Eastern Europe (Poland, Russia)

Asia Pacific (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC and S. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.


1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Molecule Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Molecule Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Molecule Type, 2022-2032
5.3.1. Corticosteroids
5.3.2. Non-Steroidal Anti-inflammatory Drugs
5.3.3. Disease-Modifying Anti-Rheumatic Drugs
5.3.4. Antimalarial Drugs
5.3.5. BLyS-specific Inhibitors or Monoclonal Antibodies
5.3.6. Immunosuppressive Agents/Immune Modulators
5.3.7. Anticoagulants
5.4. Y-o-Y Growth Trend Analysis By Molecule Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Molecule Type, 2022-2032
Deep-dive segmentation will be available in the sample on request
6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
6.3.1. Hospital Pharmacies
6.3.2. Drug Stores
6.3.3. Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
Deep-dive segmentation will be available in the sample on request
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia & Pacific
7.3.6. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.K.
8.2.1.2. Canada
8.2.2. By Molecule Type
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Molecule Type
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Molecule Type
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Molecule Type
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Molecule Type
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Molecule Type
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By Molecule Type
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Molecule Type
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Indonesia
12.2.1.4. Malaysia
12.2.1.5. Singapore
12.2.1.6. Australia
12.2.1.7. New Zealand
12.2.1.8. Rest of South Asia & Pacific
12.2.2. By Molecule Type
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Molecule Type
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Molecule Type
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Molecule Type
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. U.K.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Molecule Type
14.1.2.2. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Molecule Type
14.2.2.2. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Molecule Type
14.3.2.2. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Molecule Type
14.4.2.2. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Molecule Type
14.5.2.2. By Distribution Channel
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Molecule Type
14.6.2.2. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Molecule Type
14.7.2.2. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Molecule Type
14.8.2.2. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Molecule Type
14.9.2.2. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Molecule Type
14.10.2.2. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Molecule Type
14.11.2.2. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Molecule Type
14.12.2.2. By Distribution Channel
14.13. India
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Molecule Type
14.13.2.2. By Distribution Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Molecule Type
14.14.2.2. By Distribution Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Molecule Type
14.15.2.2. By Distribution Channel
14.16. Malaysia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Molecule Type
14.16.2.2. By Distribution Channel
14.17. Singapore
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Molecule Type
14.17.2.2. By Distribution Channel
14.18. Australia
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Molecule Type
14.18.2.2. By Distribution Channel
14.19. New Zealand
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Molecule Type
14.19.2.2. By Distribution Channel
14.20. GCC Countries
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2021
14.20.2.1. By Molecule Type
14.20.2.2. By Distribution Channel
14.21. South Africa
14.21.1. Pricing Analysis
14.21.2. Market Share Analysis, 2021
14.21.2.1. By Molecule Type
14.21.2.2. By Distribution Channel
14.22. Israel
14.22.1. Pricing Analysis
14.22.2. Market Share Analysis, 2021
14.22.2.1. By Molecule Type
14.22.2.2. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Molecule Type
15.3.3. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Anthera Pharmaceuticals
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. GlaxoSmithKline Pharmaceuticals Limited
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. ImmuPharma PLC
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Merck Serono
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Johnson & Johnson Private Limited
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Novartis AG
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. MedImmune
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Sanofi
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Teva Pharmaceutical Industries
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. HGS
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings